Lexicon to Present SCORED Analysis with BMI-Independent Heart Failure, MACE Reductions and HFpEF Quality-of-Life Data
Lexicon will present three sotagliflozin clinical analyses at ACC March 28-30, including an SCORED prespecified analysis showing heart failure and MACE reductions regardless of BMI. SOTA-P-CARDIA data show significant improvements in quality of life and physical limitation in non-diabetic HFpEF patients, plus potential epicardial fat reduction as a mechanistic insight.
1. Presentations at ACC Meeting
Lexicon will deliver three presentations at the American College of Cardiology Annual Scientific Session & Expo in New Orleans March 28-30, covering new Phase 3 SCORED and SOTA-P-CARDIA data on sotagliflozin’s cardiometabolic benefits.
2. SCORED Study Findings
A prespecified analysis of the Phase 3 SCORED trial in type 2 diabetes and chronic kidney disease patients showed sotagliflozin reduced heart failure hospitalizations and major adverse cardiovascular events consistently across all baseline BMI categories.
3. SOTA-P-CARDIA Insights
In a randomized, double-blind trial of non-diabetic HFpEF patients, sotagliflozin significantly improved health-related quality of life and physical limitation compared with placebo, with exploratory imaging suggesting selective epicardial adipose tissue reduction.
4. Implications and Next Steps
These analyses strengthen the evidence for SGLT1/2 inhibition in diverse cardiometabolic populations and support Lexicon’s plan to advance sotagliflozin into additional indications such as hypertrophic cardiomyopathy.